AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04108884 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: App measurement
Description: App measurement twice a day in the first two weeks after enrollment and twice a week (on different days) from the third week onward and whenever patients feel palpitations
Study NCT04108884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 14 day Holter ECG
Description: 14 day moblie patch Holter ECG for AF confirmation
Study NCT01382901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Study NCT01382901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01642693 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low power laser in teeth after intrusive movement
Description: Low power laser was aplied to premolar teeth under an intrusive movement to study histological changes and root resorption
Study NCT01642693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated laser in teeth with intrusive movements
Description: Simulated laser in teeth with intrusive movements for histological and root resorption changes
Study NCT03500887 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: intragastric bag
Study NCT03394274 — intervention group
Intervention type: OTHER
Intervention: restrictive and liberal transfusion
Description: hemoglobin threshold value was accepted 8g/dl. restrictive blood transfusion group was defined that if perioperative transfusion was started equal or under hemoglobin level 8 g / dL. Liberal blood transfusion group was defined as perioperative transfusion was started over hemoglobin level 8 g / dL .
Study NCT00552617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After induction of anesthesia an intubation dose of (Neuromuscular blocking agent) NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered
Study NCT00552617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arm 1) or 0.1 mg/kg vecuronium (arm 6).~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of Placebo IV was administered
Study NCT00552617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary.
Study NCT02399267 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Once daily screening
Description: RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
Study NCT02399267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Twice daily screening
Description: In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
Study NCT02399267 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PS SBTs
Description: Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS =\< 8 cm H2O with PEEP =\< 5 cm H2O.
Study NCT02399267 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-piece SBTs
Description: Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece.
Study NCT00614211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Abdominal Radical Hysterectomy
Description: In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
Study NCT00614211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic or Robotic Radical Hysterectomy
Description: In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
Study NCT02970344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Coping Skills Training (DCST)
Description: Diabetes Coping Skills Training (DCST) consist of twelve 50 minutes sessions delivered over 6 months using a faded contact model ( 6 weekly session, 3 biweekly sessions and 3 monthly sessions)
Study NCT01579344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radioiodine therapy
Description: Radioiodine therapy with NaI131
Study NCT02736539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBS 2004 (galacto-oligosaccharides)
Description: CBS 2004 active treatment
Study NCT00552617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rocuronium
Description: After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary.
Study NCT00552617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vecuronium
Description: After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV. Maintenance doses of 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.
Study NCT02736539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment
Study NCT00552617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vecuronium
Description: After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV. Maintenance doses of 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.
Study NCT00295308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: clonidine up to 0.3 mg/day oral
Study NCT01046643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol (E2)
Description: One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days; followed by one Progesterone (200mg) once a day, at the same time each day, for 10 days to slough endometrial lining; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
Study NCT01046643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone (P10) x90
Description: One Progesterone capsule (200mg) once a day, at the same time each day, for 90 days; followed by one Placebo capsule (to mirror Progesterone capsule to slough endometrial lining in Estradiol recipients) once a day, at the same time each day, for 10 days ; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
Study NCT01046643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone (P10) x10
Description: One Progesterone (200mg) capsule once a day for 10 days, to slough endometrial lining for patients taking Estradiol. Patients taking Progesterone will take an equivalent Placebo capsule during this time period.
Study NCT00295308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsules daily
Study NCT01052038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: Placebo administration
Study NCT01052038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0.05mg/kr administration
Description: Dexamethasone 0.05mg/kr administered in 100ml of sterile saline solution prior to the start of surgery.
Study NCT01052038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0.1mg/kg
Description: Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to the beginning of surgery.
Study NCT01408589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine, Strattera
Description: Atomoxetine at 0, 40, 60, 80 mg/day was given for 5 days, all subjects took two capsules per day for 5 days; all active dose groups received 40 mg/day for first 3 days and where then dose escalated to dosage group assigned.
Study NCT01408589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine, Strattera
Description: Atomoxetine at 0, 40, 60, 80 mg/day was given for 5 days, all subjects took two capsules per day for 5 days; all active dose groups received 40 mg/day for first 3 days and where then dose escalated to dosage group assigned.
Study NCT00744536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and melphalan
Description: Lenalidomide (Revlimid) 10 mg po daily for 21d/28 Melphalan (Melphalan) 2 mg po daily for 21d/28
Study NCT04574544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Supplementation
Description: The 25 supplemented children had received an oral zinc supplement per day for 14 days and had no dietary restrictions.
Study NCT02833558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PuraStat®
Description: PuraStat® gel is applied through a safe catheter delivery system (via endoscope) over the bleeding point
Study NCT02833558 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electrocautery
Description: Electrocautery (coagulation current) to stop bleeding during ESD
Study NCT01921725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hydrophilic-based dressing (KoCarbonTM)
Description: BCT Hydrophilic Wound Dressing consists of PET non-woven, activated carbon fiber (ACF) cloth and PE film. The PET non-woven is vapor permeable to allow air exchange for the wound. The absorbent ACF absorbs exudate, bacteria and odor to create an effective barrier. Furthermore, far infrared ray (FIR) emitted from ACF accelerates blood circulation and metabolism to reduce healing period. The PE film helps to minimize wound trauma at dressing changes.
Study NCT02733458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GELAD
Description: Gemcitabine, 1.0g/m2/d IV, day 1 Etoposide, 60mg/m2 IV, day 1 to day 3 Dexamethasone, 40mg/d IV, day 1 to day 4 Pegaspargase, 2000IU/m2/d IM, day 4
Study NCT02733458 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy: 50-56Gy
Study NCT01068795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin
Description: enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
Study NCT04574544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education of mothers
Description: Nutritional information was delivered to each mother to facilitate a change in bad eating habits observed, improve knowledge, attitudes and skills of mothers on child nutrition. The anthropometric and biochemistry parameters of children were taken before and after the maternal nutrition education
Study NCT03112616 — intervention group
Intervention type: OTHER
Intervention: Vibration sessions
Description: The patients will undergo a program of 10 sessions of vibrations of the neck muscle, each of 10 minutes, during a period of 15 days at the rate of one session per day.
Study NCT03908684 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound Imaging
Description: Ultrasound Spectroscopy assess changes in five different ultrasound spectroscopic parameters over different times during treatment with radiotherapy as predictors of tumour shrinkage and pathologic complete response. Ultrasound parameters investigated will include mid-band fit (related to image intensity),spectroscopic slope (backscatter versus frequency), spectroscopic intercept, histogram fit size and shape parameters which can be used as estimates of scatterer size and concentration.
Study NCT00637793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGX267
Description: 2 capsules in the am of each treatment period
Study NCT00793910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 300 mg taken by mouth thrice daily for 7 days
Study NCT00793910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (sugar pill) taken by mouth thrice daily for 7 days
Study NCT02020551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Spray
Study NCT02020551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01039116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity
Description: High-intensity intervention, Experimental. Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.
Study NCT01039116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Intensity
Description: Low-intensity intervention, Active comparator. Participants were provided with educational materials 4 times yearly.
Study NCT03594045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban is an anticoagulant that works by inhibiting the coagulation factor, Factor Xa.
Study NCT00961974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Ambassador Intervention
Description: Care Ambassador provides additional monthly outreach (by phone or e-mail) to families between clinic visits.
Study NCT00961974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Intervention
Description: A psychoeducational intervention module is reviewed with the family by the Care Ambassador at each clinic visit. The intervention focuses on incorporating intensive therapy into the daily routine of the child through positive family support for blood glucose monitoring and healthy eating. The intervention modules review positive family communication, realistic expectations, ways to avoid perfectionism and maintain family involvement, prevention of hypoglycemia, avoidance of diabetes-specific family conflict, and approaches to reducing diabetes burnout.
Study NCT03931434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aged Garlic Extract (AGE)
Description: 2400mg of Aged Garlic Extract (AGE)
Study NCT03931434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01511952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Intervention
Description: Applied by randomization-live at bassinet in the AM or PM Gato Box, Ocean Disc or parent-selected lullabies
Study NCT00637793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NGX267
Description: 2 capsules in the am of each treatment period
Study NCT01511952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Remo Ocean disc Gato box Music therapist's or Parent's preferred lullaby or 'Twinkle'
Study NCT02878993 — intervention group
Intervention type: DEVICE
Intervention: Recording of diaphragm EMG
Description: Recording of diaphragm EMG prior to extubation using surface diaphragm electromyography
Study NCT04117828 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dates
Description: Phoenix dactylifera, commonly known as date or date palm is a flowering plant species in the palm family, Arecaceae. Dates are the fruit of the date palm tree, which is grown in many tropical regions of the world. Dates provide a wide range of essential nutrients, and has certain protective effects on health of individuals.
Study NCT04117828 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dates
Description: Phoenix dactylifera, commonly known as date or date palm is a flowering plant species in the palm family, Arecaceae. Dates are the fruit of the date palm tree, which is grown in many tropical regions of the world. Dates provide a wide range of essential nutrients, and has certain protective effects on health of individuals.
Study NCT00093145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: Administered by intravenous infusion.
Study NCT00093145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin dose was calculated using a modified Calvert formula (creatinine clearance was substituted for GFR): Total dose (mg) = (target AUC) x (creatinine clearance + 25). Note: AUC = 6 was initially targeted, but could be decreased due to toxicity.
Study NCT00093145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin®
Description: Administered by IV infusion
Study NCT03000894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: This CBT-I is a 4 sessions 60-90 minutes group-based therapy administered by a nurse therapist. Each session has 6-8 participants.
Study NCT02255110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: TH-302 will be administered at a dose of 300 milligram per square meter (mg/m\^2) by intravenous infusion over 30 minutes on Days 1 and 8 of every 21-day cycle until the evidence of significant treatment-related toxicity or progressive disease.
Study NCT02255110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered at a dose of 75 mg/m\^2 by intravenous injection (over at least 5 minutes) or by intravenous infusion over 6-96 hours on Day 1 of every 21-day cycle starting 2 to 4 hours after completion of TH-302 administration until the evidence of significant treatment-related toxicity or progressive disease.
Study NCT01528228 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS Treatment with functional or disabled unit
Description: TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.
Study NCT01528228 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS Treatment with functional or disabled unit
Description: TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.
Study NCT01060865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 150 mg during the first two weeks , 300 mg for another 10 weeks
Study NCT04257370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kerecis™ Omega3 Wound
Description: Kerecis™ Omega3 Wound is decellularised, intact fish skin from North Atlantic cod fish. Kerecis™ Omega3 Wound is FDA approved and EU cleared for the treatment of diabetic ulcers, chronic vascular ulcers, venous ulcers, trauma wounds (including abrasions, lacerations, and skin tears), acute surgical wounds (including debridement, amputation, and donor sites), surgical wounds (dehiscence or failed healing after surgery), imminent failure of STSG, and post-injection necrosis.
Study NCT04257370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care wound treatment as defined by the local site, including debridement of the wound, standard wound dressing, and proper offloading of the wound site.
Study NCT02073045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive educational handouts
Study NCT02073045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lymphedema survey
Description: Ancillary studies
Study NCT00152295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil/Premarin
Description: 10 mg (2-5mg tablets) asoprisnil and 0.625 mg Premarin tablets, oral daily for 6 months
Study NCT03877367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity manipulation
Description: An upper extremity (glenohumeral, humeroulnar and radioulnar joints, bilaterally) or a lower extremity (coxofemoral, tibiofemoral, and tibiotalar, bilaterally) manipulation series.
Study NCT01198600 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual contact lens
Description: Hydrogel or silicone hydrogel contact lens per participant's habitual brand and prescription
Study NCT01198600 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens
Description: Commercially marketed silicone hydrogel contact lens
Study NCT01198600 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens cleaning and disinfecting system (ClearCare)
Description: Commercially marketed, hydrogen peroxide-based contact lens care system
Study NCT02950493 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: perflutren lipid microsphere
Description: Definity and Lumason are tools for diagnosis used in echocardiography. Compare activated Definity or Lumason with compressed Definity or Lumason.
Study NCT03799575 — intervention group
Intervention type: BEHAVIORAL
Intervention: Transmission Electron Microscopy analysis
Description: Morphology of two vitreal side of Internal Limiting Membrane in contact
Study NCT04682639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Participants will receive etrasimod tablet by mouth, once daily during the 24-week Double-Blind and 28-week Extension Treatment Periods.